Evidence map›Paper›PMID 30292745›Full record

Trial reportBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2019

Over-expression of PD-1 Does Not Predict Leukemic Relapse after Allogeneic Stem Cell Transplantation.

Prachi Jain, Xin Tian, Stefan Cordes, Jinguo Chen, Caroline R Cantilena, Christian Bradley, Reema Panjwani, Fariba Chinian, Keyvan Keyvanfar, Minoo Battiwalla and 3 more

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. The Role of Immune Checkpoints after Cellular Therapy.International journal of molecular sciences · 2020
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Prachi JainHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Xin TianOffice of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Stefan CordesHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Jinguo ChenCenter for Human Immunology, Autoimmunity, and Inflammation, National Institutes of Health, Bethesda, Maryland.
Caroline R CantilenaHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Christian BradleyHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Reema PanjwaniHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Fariba ChinianHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Keyvan KeyvanfarHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Minoo BattiwallaHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Pawel MuranskiHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
A John BarrettHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Sawa ItoHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: itos2@mail.nih.gov.
National Institutes of Health · US

Funding

Center for Human Immunology ZICAI001226 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHERRY, JAMES · 2018 to 2025
$34.1M
Characterization and improvement of graft versus leukemia effectsZIAHL006107 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI BARRETT, AUSTIN JOHN · 2011 to 2017
$8.6M
Graft-versus-leukemiaZIAHL002342 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI BARRETT, AUSTIN JOHN · 2009 to 2010
$6.3M
Intramural NIH HHS Z99 HL999999Intramural NIH HHS ZIA HL002342Intramural NIH HHS ZIA HL006107
6 · The paper itself

Abstract

Blockade of the T-cell exhaustion marker PD-1 to re-energize the immune response is emerging as a promising cancer treatment. Relapse of hematologic malignancy after allogeneic stem cell transplantation limits the success of this approach, and PD-1 blockade may hold therapeutic promise. However, PD-1 expression and its relationship with post-transplant relapse is poorly described. Because the donor immunity is activated by alloresponses, PD-1 expression may differ from nontransplanted individuals, and PD-1 blockade could risk graft-versus-host disease. Here we analyzed T-cell exhaustion marker kinetics and their relationship with leukemia relapse in 85 patients undergoing myeloablative T-cell-depleted HLA-matched stem cell transplantation. At a median follow-up of 3.5 years, 35 (44%) patients relapsed. PD-1 expression in CD4 and CD8 T cells was comparably elevated in relapsed and nonrelapsed cohorts. Helios

Indexed as

LeukemiaStem Cell TransplantationAdultAllograftsBiomarkers, TumorDisease-Free SurvivalFemaleFollow-Up StudiesGene Expression Regulation, LeukemicHumansMaleMiddle AgedNeoplasm ProteinsProgrammed Cell Death 1 ReceptorRecurrenceSurvival RateBiomarkers, TumorNeoplasm ProteinsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorBiomarkerGraft-versus-leukemia effectPost-transplant relapse

Identifiers

PMID30292745
PMCPMC10478036
OpenAlexW2895558053

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.